Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.54 |
| ▸ | PDE4A | P27815 | 15/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202997 | 0.87 | PDE4D (0.44) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL720382 | 0.83 | PDE4D (0.62) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL5794099 | 0.83 | PDE4D (0.65) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL6571717 | 0.80 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL4388724 | 0.78 | L3MBTL1 (0.34) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5950136 | 0.77 | MAPT (0.43) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7425565 | 0.74 | PDE4D (0.59) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL7065703 | 0.73 | PDE4A (0.54) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL7534706 | 0.73 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30084836 | 0.73 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006528229-A | — | — | 2006-12-14 | — | — | JP | claimed |
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | ALTANA PHARMA AG (DE) | 2006-04-13 | — | — | US | claimed |
| EP-1628682-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA Pharma AG (DE) | 2006-03-01 | — | — | EP | claimed |
| US-6998410-B2 | Compositions | ALTANA PHARMA AG (DE) | 2006-02-14 | — | — | US | claimed |
| EP-1610788-A1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND AN ANTICHOLINERGIC AGENT SELECTED FROM IPRATROPIUM, OXITROPIUM AND TIOTROPIUM SALTS FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA Pharma AG (DE) | 2006-01-04 | — | — | EP | claimed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | claimed |
| EP-1567136-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA Pharma AG (DE) | 2005-08-31 | — | — | EP | claimed |
| WO-2004103407-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-12-02 | — | — | WO | claimed |
| WO-2004084897-A1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND AN ANTICHOLINERGIC AGENT SELECTED FROM IPRATROPIUM, OXITROPIUM AND TIOTROPIUM SALTS FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2004-10-07 | — | — | WO | claimed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | claimed |
| WO-2004047817-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA PHARMA AG (DE) | 2004-06-10 | — | — | WO | claimed |
| US-8648100-B2 | Roflumilast for the treatment of pulmonary hypertension | TAKEDA GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20090215836-A1 | Roflumilast for the Treatment of Pulmonary Hypertension | NYCOMED GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1874308-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | Nycomed GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874309-A1 | ROFLUMILAST FOR THE TREATMENT OF PULMONARY HYPERTENSION | Nycomed GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1161239-A2 | 3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXY-N-(3,5-DICHLOROPYRID-4-YL)BENZAMIDE IN THE TREATMENT OF MULTIPLE SCLEROSIS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000066123-A1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000053182-A2 | 3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXY-N-(3,5-DICHLOROPYRID-4-YL)BENZAMIDE IN THE TREATMENT OF MULTIPLE SCLEROSIS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-09-14 | — | — | WO | disclosed |
| EP-0977577-A1 | COMPOSITIONS FOR THE TREATMENT OF ARDS OR IRDS CONTAINING 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-4-PYRIDINYL)-4-(DIFLUOROMETHOXY)BENZAMIDE AND LUNG SURFACTANT | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998035683-A1 | COMPOSITIONS FOR THE TREATMENT OF ARDS OR IRDS CONTAINING 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-4-PYRIDINYL)-4-(DIFLUOROMETHOXY)BENZAMIDE AND LUNG SURFACTANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | PDE4A, PDE12, PDE4B | PDE4D 8/4885PDE4B 3/4885PDE4A 1/4885 |
| US-20090215836-A1 | Roflumilast for the Treatment of Pulmonary Hypertension | PDE5A, PDE12, PDE3A | PDE4D 12/4885PDE4B 8/4885PDE4A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.